CDH17 (US10858438B2 Biosimilar) Recombinant Monoclonal Antibody

1. CDH17 has a role in altering MMP-2 expression via canonical NF-kappaB signalling in human gastric cancer PMID: 29783070
2. Data show that alteration in beta-catenin expression, a core component of the CDH17/beta-catenin axis, in tumors affects serine peptidase inhibitor Kazal type 1 (SPINK1) serum levels in hepatocellular carcinoma (HCC) patients. PMID: 28631187
3. However, CDH17 expression was significantly elevated in patients with stage II and III gastric cancers compared to that in healthy controls (p= 0.023 and p= 0.037, respectively). PMID: 28453457
4. CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. PMID: 27580354
5. CDH17 is a sensitive marker for midgut WDNETs, and the CDH17+/CDX2-/TTF1- phenotype was found to be sensitive (92%) and specific (91%) for hindgut well-differentiated neuroendocrine tumours (WDNETs). PMID: 25388236
6. Using a lentiviral system as a delivery mediator of RNA interference, we found that inhibition of CDH17 can lead to reduce proliferation and increase apoptosis of gastric cancer cell line MKN28 in vitro and significantly diminish their tumorigenicity in vivo. Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer. PMID: 27909714
7. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. PMID: 28029907
8. These data indicate that knockdown of LIcadherin facilitates the invasion of cancer cells by degrading extracellular matrix components via activation of MMP2 and 9, and increases cancer cell adhesion and migration via altered expression of galectin3. PMID: 27035870
9. Fascin-1 expression, cadherin-17 expression, tumor size, and differentiation were independent risk factors for GC. PMID: 26743780
10. Mutations in CDH17 gene is associated with idiopathic hypereosinophilic syndrome. PMID: 26497854
11. Review/Meta-analysis: data reflect the role of CDH17 in tumor proliferation and metastasis among gastric cancer patients. PMID: 25834338
12. CDH17 is a sensitive (81%) and highly specific (100%) marker for metanephric adenoma. PMID: 25768256
13. RGD motif present in cadherin 17 induces integrin activation and tumor growth PMID: 25336636
14. Data suggest that combined tumor expression of CDH17 (cadherin-17) and SATB2 (special AT-rich sequence binding protein 2) may be used as diagnostic biomarkers in subjects with medullary carcinoma of the large intestine (colon; cecum). PMID: 24437456
15. Data reveal a new function for CDH17, which is to regulate alpha2beta1 integrin signaling in cell adhesion and proliferation in colon cancer cells for liver metastasis. PMID: 23604127
16. The SNPs of the CDH17 gene c.2216 A>C might be clinically important in the prognosis of colorectal carcinoma. PMID: 23326130
17. This study demonstrates that the secreted form of cadherin-17 (ectodomain) is truncated at the C-terminus. PMID: 23557862
18. results identify CDH17 as a biomarker of gastric carcinoma and attractive therapeutic target for this aggressive malignancy. PMID: 23554857
19. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFkappaB signaling pathway. PMID: 23298905
20. LI-cadherin is a sensitive marker of intestinal metaplasia and can be helpful for early histologic diagnosis of Barrett's esophagus (BE); it is not, however, significantly different between BE with and without intestinal epithelial neoplasia. PMID: 23053896
21. Up-regulation of cadherin 17 is associated with epithelial ovarian cancer progression. PMID: 22810971
22. Report less aggressive behavior of gastric tumors after CDH17 gene knockdown. PMID: 22791949
23. CDH17 was positively associated with larger tumor size, deeper invasion, diffuse/mixed histotype, LVI, and LNMM, predicting a poor prognosis in pN0 gastric cancer. PMID: 22009269
24. LI cadherin is associated with an intestinal phenotype and an 'intestinal pathway' of carcinogenesis in intraductal papillary mucinous neoplasm. PMID: 22286087
25. we proposed that CDH17 may be an oncogene up-regulating invasive features of gastric cancer cells PMID: 20393816
26. CDH17 expression may be well preserved during the metastatic process and therefore be a useful marker for identifying colorectal adenocarcinomas in a metastatic setting with an unknown primary site PMID: 21323956
27. Targeting CDH17 in HCC can inhibit tumor growth and inactivate Wnt signaling pathway in concomitance with activation of tumor suppressor genes.[review] PMID: 20580775
28. CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract. PMID: 20444732
29. identified the minimal promoter region of CDH17 that is regulated by HNF1alpha and CDX2 transcriptional factors; Suppression of HNF1alpha and CDX2 expression by siRNA down-regulated expressions of CDH17 and cyclin D1 and the viability of HCC cells PMID: 20568120
30. Li-cadherin participates in the multiple steps of invasion and metastasis in a colorectal cancer cell line. PMID: 20204409
31. CDH17 maybe a positive regulator for proliferative, adhesive, and invasive behaviors of gastric cancer. PMID: 20500517
32. Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer. PMID: 20398667
33. Loss of LI-cadherin results in up-regulation of MTF-1 and PlGF, thereby regulating angiogenesis in intrahepatic cholangiocarcinoma PMID: 19956853
34. High xpression of liver-intestine cadherin and its possible interaction with galectin-3 is associated with ductal adenocarcinoma of the pancreas PMID: 12824888
35. tumor staging and LI-cadherin expression were found to be independent factors associated with lymph node metastasis. PMID: 15178443
36. LI-cadherin may have a role in lymph node metastasis and progression of human colorectal carcinoma PMID: 15279905
37. Aberrant alternative splicing of LI-cadherin is associated with hepatocellular carcinoma PMID: 15701831
38. The functional T-G haplotype of CDH17 (651 C>T and IVS6+35A>G) is a genetic susceptibility factor for the development of Hepatocellular carcinoma (HCC) in a Chinese population. PMID: 16951245
39. Reduced expression of liver intestine-cadherin had a significant correlation with tumoral dedifferentiation and short overall survival in colorectal cancer. PMID: 17828401
40. combined detection of CDH17/CDX2 co-expression may benefit us in predicting the prognosis of gastric carcinoma. PMID: 18353622
41. Cadherin-17 is a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system. PMID: 18552820
42. CDH17 is a novel oncogene in hepatocellular carcinoma. CDH17 is a biomarker and attractive therapeutic target for this aggressive malignancy. PMID: 19676131

Show More

Hide All

HGNC: 1756

OMIM: 603017

KEGG: hsa:1015

STRING: 9606.ENSP00000027335

UniGene: Hs.591853